Teva Canada Limited, headquartered in Toronto, is part of Teva Pharmaceutical Industries Ltd., the world’s largest generic drug maker. We’re proud to have been part of Canadian healthcare for more than 50 years, to market more than 400 medications across the country and to employ more than 1,000 Canadians. If you’re looking for information about our company, please contact Public Affairs at Teva Canada Limited at Public.Affairs@tevacanada.com
Latest news from Teva Canada
Teva Canada Limited is voluntarily recalling Teva-Valsartan/HCTZ 80/12.5 mg, 160/12.5 mg, 160/25 mg and 320/12.5 mg tablets, with the specified lot numbers. (August 17)
Teva Canada Limited is voluntarily recalling Teva-Valsartan/HCTZ 320 mg/25 mg tablets and ACT Valsartan 40 mg, 80mg, 160 mg and 320 mg tablets with the specified lot numbers. (July 9, 2018)
Launch of PrTeva-Cyclosporine ophthalmic emulsion, the first generic version of PrRestasis® in Canada for the treatment of dry eye disease. (May 10, 2018)
Launch of CACT Methylphenidate ER tablets, a generic version of CConcerta® for the treatment of ADHD (March 22, 2018)
Canadian pharmacists are becoming vaccine providers in their communities (July 27, 2018)
View our global media page for news from Teva around the world.